Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)

This study has been completed.
Pharmbio Korea Co., Ltd.
Information provided by (Responsible Party):
Sang Myung Woo, National Cancer Center, Korea Identifier:
First received: April 25, 2012
Last updated: April 13, 2015
Last verified: April 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2014
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)